Carprieve

Carprofen

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carprieve

Property	Description
Active ingredient	Carprofen (INN)
Form	Caplets, chewable tablets, injectable solution
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use	Relief of pain and inflammation
Origin	Synthetic compound
Brand Differentiating Feature	Pork liver-flavored oral forms

Carprieve is a pharmaceutical brand containing Carprofen as its single active ingredient. The compound is a synthetic entity belonging to the propionic acid derivative chemical family. The general therapeutic purpose of this medication is to help alleviate the symptoms of pain and inflammation, a function that is clinically recognized across pharmacological studies.

The Composition and Origin of Carprieve

The composition of Carprieve is fundamentally defined by the presence of Carprofen, the nonproprietary name for the active chemical component. Carprofen is chemically derived, distinguishing it as a synthetic compound that is part of the propionic acid derivative group, a classification shared with numerous other agents used for mitigating inflammation. While Carprofen was previously available for human use, it is now exclusively utilized in veterinary medicine, specifically intended for canines.

Carprieve's Classification and Differentiating Features

Carprieve is definitively classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This pharmacological class dictates that the medication’s core function is to reduce the body’s inflammatory responses. As a brand, Carprieve is offered in distinct formulations, including a pork liver-flavored chewable tablet, a feature intended to improve ease of administration compared to standard, unflavored caplets. The availability of both caplets and injectable solution further differentiates the product line by offering versatility in treatment.

The Available Dosage Forms

The active ingredient Carprofen is formulated for delivery in several distinct dosage forms. These include solid forms for oral administration, such as scored caplets and the uniquely flavored chewable tablets. Additionally, a sterile injectable solution is available, which permits parenteral delivery. This variety in preparation ensures the medicine can be utilized across different settings and patient needs for the purpose of managing pain and swelling.

What side effects are possible with Carprieve?

Official Adverse Reactions and Safety Profile

The official safety information for Carprofen (Carprieve) documents possible adverse reactions primarily affecting the Gastrointestinal system, which are categorized as the Most Frequently Reported effects in regulatory materials. Events affecting the Hepatic (Liver) and Renal (Kidney) systems are also documented.

Key adverse reactions listed by official labels include:

Common Effects: Vomiting, diarrhea, soft stools, decreased appetite (inappetence), and lethargy. These generally occur within the first week of treatment.
Organ System Effects: Reactions may involve the Nervous System (e.g., incoordination, seizures), Urinary System (e.g., increased urination, increased water consumption), and the Blood and Lymphatic System.

Serious and Rare Adverse Reactions

While rare, official regulatory documents list Serious Adverse Reactions that may occur with or without warning. These include Gastrointestinal Ulceration and Bleeding (which may manifest as dark or tarry stools), Acute Hepatic Toxicity/Failure, and Acute Renal Failure. These rare events can, in very rare situations, result in fatal outcomes.

Safety Constraints and Risk Patterns

The label defines specific constraints and populations that require particular caution or where use is contraindicated:

Pre-existing Conditions: The medicine is not to be used in animals with pre-existing cardiac, hepatic, or renal disease, or in those with evidence of gastrointestinal ulceration or bleeding.
Hydration Status: Use must be avoided in dehydrated, hypovolaemic, or hypotensive animals due to the potential for increased renal toxicity.
Interactions: Concomitant use with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids is to be avoided due to a documented increase in the risk of adverse events.
Exposure: Long-term exposure is associated with a higher risk of adverse reactions, and a patient's response must be monitored at regular intervals as defined in regulatory texts.

This regulatory structure emphasizes that the risk profile is primarily centered on possible gastrointestinal effects, alongside the necessity to avoid the medication in specific patient populations with compromised organ function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Carprofen establishes specific manifestations and required emergency actions related to overdose. Overdose may initially present with clinical signs such as vomiting, diarrhea (which may contain blood), lethargy, and decreased appetite. However, the officially documented severe manifestations primarily involve toxicity to major organ systems, including acute renal failure, acute hepatic toxicity, and severe gastrointestinal ulcerations that can lead to perforation.

Immediate medical intervention is strictly required upon suspicion of overdose or observation of any signs of intolerance. The regulatory information mandates that the product be discontinued and professional medical help be contacted immediately. Severe cases may exhibit neurological signs like seizures or stupor, which demand urgent care.

Management procedures described in regulatory sources are strictly symptomatic and supportive. This includes immediate gastrointestinal decontamination, administration of IV fluids for systemic and renal support, and the continuous monitoring of hepatic and renal function. No specific chemical antidote is listed in the official prescribing information. Patients with existing hepatic or renal dysfunction are cited in official labeling as being at higher risk for severe overdose outcomes.

Therapeutic Uses of Carprieve

What Carprieve Treats: Main Uses and Benefits

Carprieve is commonly used in therapeutic contexts involving symptomatic support for dogs. The active ingredient is applied across domains where additional symptomatic support is needed, primarily addressing inflammation and pain.

The medication is generally used to provide supportive relief for conditions characterized by periods of heightened symptoms such as osteoarthritis and degenerative joint disease. It is also applied in clinical settings that involve acute symptom patterns, specifically the management of discomfort and swelling following surgical procedures. This supportive action helps address symptom clusters that may become intense or disruptive, including generalized fever.

“Carprieve assists with maintaining functional stability and supports general well-being during symptomatic phases.”

In summary, the medication is relevant for easing symptoms related to chronic musculoskeletal discomfort, acute post-surgical symptoms, and systemic inflammatory manifestations. This supports maintaining a sense of stability and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Support for Joint Discomfort Symptoms
Carprieve is commonly used to help ease symptoms related to physical discomfort and stiffness in conditions like chronic joint disease.

Eligibility and Restrictions for Use

Carprieve is a veterinary medicine and is officially regulated for use exclusively in dogs (canines). The product is absolutely contraindicated and must not be administered to cats or to humans.

Regulatory documents strictly define the population ineligible for use based on systemic health and pre-existing conditions. Use is contraindicated in dogs with diagnosed cardiac disease, renal disease, or hepatic disease. It is also prohibited in dogs with a history of hypersensitivity to carprofen or other nonsteroidal anti-inflammatory drugs (NSAIDs), or in those with evidence of gastrointestinal ulceration or bleeding.

Eligibility is further restricted by life stage. Safe use has not been established in pregnant, lactating, or breeding dogs. The medicine is also not established for use in puppies under six weeks of age. Use is not recommended and requires special consideration in dogs that are dehydrated or hypovolaemic, or in aged (geriatric) dogs, due to potential risks linked to these physiological states.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Carprieve (Carprofen) is defined by both pharmacodynamic and pharmacokinetic patterns, with restrictions on co-administration of certain drug classes.

It is a formal restriction that Carprofen must not be administered concurrently with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or with Glucocorticoids (Corticosteroids). This prohibition is due to the documented risk of additive toxicity, particularly an increased risk of gastrointestinal ulceration and perforation.

Beyond strict prohibition, other combinations require avoidance or caution. The official label advises against concurrent administration with Anticoagulants due to the potential for a documented increased bleeding tendency. Similarly, co-administration with Potentially Nephrotoxic Drugs should be avoided or approached cautiously due to the additive risk of renal injury.

A key pharmacokinetic consideration is that Carprofen is highly protein-bound and may compete with other highly protein-bound agents, potentially resulting in toxic effects due to altered free drug exposure. A mandatory treatment-free period or washout time must be strictly observed when switching treatment from a prohibited NSAID or a corticosteroid. The risk of renal toxicity from certain co-administered agents is formally noted to be heightened in populations that are dehydrated or have existing renal, cardiovascular, and/or hepatic dysfunction.

Mechanism of Action

Mechanism of Action: Pharmacodynamics

Carprieve's mechanism is defined by its action as a reversible inhibitor with a preferential affinity for the Cyclooxygenase-2 ( COX-2) enzyme. By inhibiting COX-2, which is highly expressed during inflammation, the drug restricts the conversion of arachidonic acid into pro-inflammatory prostaglandins ( PGE2). The subsequent reduction in PGE2 concentration initiates a molecular cascade that modulates the thermoregulatory set point in the hypothalamus and reduces localized vascular hyperpermeability.

Beyond this primary action, the mechanism engages the nociceptive signaling pathway by diminishing the sensitization of peripheral nociceptors, which are normally prone to activation by prostaglandins. Evidence also suggests that, via the inhibition of the FAAH enzyme, the mechanism impedes the degradation of certain endogenous analgesic compounds, contributing to the overall modulation of pain signaling. The final physiological effect profile is a composite of S(+)-driven COX inhibition and R(-)-driven non- COX effects due to the drug's nature as a racemic mixture.

Dosage and Administration Information

Administration Routes and Forms

Carprieve (Carprofen) is administered through two official routes: orally via caplets or chewable tablets, and by subcutaneous injection for the sterile solution. The injectable form is designated strictly for subcutaneous use and is often utilized pre-operatively for procedural pain management. Safety for intravenous or intramuscular delivery is not established.

Standard Dosing Regimens

The core usage instruction mandates a total daily dose of 4.4 mg/kg of body weight (or 2 mg/lb), calculated precisely based on the patient's weight. This total dose can be administered in one of two approved frequency patterns: as a single dose once daily or divided into two equal administrations of 2.2 mg/kg given every 12 hours.

Contextual and Duration Instructions

Oral forms may be given with or without food, and the scored caplets allow for dose adjustment in half-caplet increments to meet the required dose. For chronic treatment, official guidelines permit the dose to be reduced to a lower single daily dose of 2 mg/kg after seven days of initial use. Post-operative use of the injectable form is typically followed by a transition to oral tablets for up to five days. Use of this medication is not recommended for animals less than six weeks of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carprofen (Carprieve)

Evidence for Use in Chronic Joint Discomfort (Osteoarthritis)

The clinical evidence for the use of Carprofen exists for studies that examined symptoms related to chronic joint discomfort in canines, and is primarily drawn from Randomized Controlled Trials (RCTs) and longer-term observational studies. The research explored how symptoms change over time in animals with naturally occurring osteoarthritis and other degenerative joint conditions. Researchers evaluated outcomes related to physical discomfort and daily functioning.

In these studies, measurements included both objective analyses, such as assessing limb function via force plate technology (which is used to measure weight distribution), and subjective evaluations, such as owner and veterinarian assessments of stiffness and mobility. Studies reported patterns in the measured outcomes related to limb function over the observed time intervals.

Evidence for Use in Acute Postoperative Pain

Research exploring the use of Carprofen for temporary physiological imbalance following surgery includes controlled clinical studies. These studies focused on episodes where acute discomfort became more noticeable. The populations studied were canines undergoing both soft tissue surgery and more complex orthopedic procedures.

Studies monitored outcomes linked to signs of swelling and irritation, focusing on data from validated behavioral and physiological pain assessment tools. Research describes patterns related to symptom intensity and the changes measured during the study period, typically concentrated in the first 48 hours post-procedure.

What is Still Uncertain About the Research

While extensive research has been conducted, the available follow-up durations were limited for fully characterizing the outcomes of long-term continuous use. Long-term effects are not fully established, and there is limited information for outcomes beyond 12 weeks. Comparative evidence against all available treatment options is often limited. Studies rely on subjective behavioral observation or owner feedback, which limits certainty in some assessments.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Carprieve (FAQ)

Q: How long does the effect of one dose of Carprieve usually last?

A: Studies on the drug’s processing by the body (pharmacokinetics) indicate that the terminal half-life of Carprofen in dogs is approximately 8 to 11.7 hours after a single administration. The half-life is the time it takes for the concentration of the medication in the body to decrease by half.

Q: Does Carprieve require a prescription or can it be bought over the counter?

A: According to regulatory documents, this medication is restricted to use by or on the order of a licensed veterinarian in major jurisdictions. It is not an over-the-counter product.

Q: What happens if a person occasionally misses a dose of Carprieve?

A: Official regulatory information generally describes that if a dose is missed, it can be administered when remembered, unless it is close to the time for the next scheduled dose. In that scenario, regulatory texts indicate the missed dose may be skipped, and the regular schedule may be resumed. Doses should not be doubled.

Q: Is it necessary to have blood tests done while taking Carprieve?

A: For long-term use of this type of nonsteroidal anti-inflammatory drug (NSAID), regulatory guidance indicates that regular check-ups are warranted. These check-ups typically include periodic blood and urine tests to monitor important health metrics, such as liver and kidney values.

Q: Where can I find the official prescribing information for Carprieve?

A: Official prescribing information is made available through government resources. These include databases like the FDA's DailyMed or Animal Drugs @ FDA, or the European Medicines Agency's (EMA) Summary of Product Characteristics (SmPC).

Q: How does Carprieve compare to NSAIDs like ibuprofen or naproxen?

A: Carprieve, which contains Carprofen, is an NSAID approved for use exclusively in dogs. Regulatory documents stress that this product should not be compared or interchanged with NSAIDs intended for human use, such as ibuprofen or naproxen, as human NSAIDs can be toxic to dogs.

Q: Is Carprieve considered a non-narcotic or non-addictive medication?

A: The product is classified by regulatory authorities as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification means it is not considered a narcotic or controlled substance.

Q: Is there a patient information leaflet available for Carprieve?

A: Yes, regulatory documents and product packaging often refer to a 'package insert' or 'information for dog owners.' This leaflet provides detailed safety, administration, and usage information as defined by the authorizing bodies.

Q: Are there specific instructions for stopping the use of Carprieve?

A: Regulatory safety information indicates that if any adverse reactions (side effects) occur or are suspected, discontinuation of the medicine may be considered immediately. It is advised to contact a veterinarian in such situations.

Q: Do regulatory bodies classify Carprieve as a high-risk medication?

A: Regulatory documents do not label the product as 'high-risk,' but the official label does contain important safety warnings. These warnings highlight the potential for serious, rare side effects and strictly list contraindications, especially for patients with pre-existing heart, liver, or kidney problems.

Q: Can Carprieve interact negatively with supplements or vitamins?

A: Official warnings focus on drug-to-drug interactions, particularly cautioning against use with other highly protein-bound agents. The general NSAID interaction profile indicates that supplements with antiplatelet properties may also require caution when used alongside this medication.

Q: What are the signs of a possible allergic reaction to Carprieve?

A: The label notes hypersensitivity as a contraindication. Changes in the skin, such as redness, itching, or scabs, are signs that require close monitoring and prompt communication with a veterinary professional.

Q: Can Carprieve be taken if I have high blood pressure?

A: The official product information indicates that the use of this medication in dogs with pre-existing cardiac disease is discouraged. The use of any NSAID can affect the patient's fluid status, which is a key consideration.

Q: Are there different strengths or formulations of Carprieve available?

A: Yes, the product is available in several forms, including tablets (caplets) and an injectable solution. The caplets are typically offered in multiple strengths, such as 25 mg, 75 mg, and 100 mg.

Q: What should be done if someone accidentally takes too much Carprieve?

A: If there is any suspicion of an overdose, it is important that a veterinarian or poison control center is contacted immediately. Official safety documents warn that severe toxicity can occur, potentially leading to serious outcomes like kidney failure or gastrointestinal bleeding.

Q: What percentage of people report serious side effects from Carprieve?

A: Official data indicates that serious side effects, which include severe gastrointestinal or organ system failure, are reported in rare situations. The product label uses qualitative terms like 'rare' but does not provide a specific reporting percentage or rate.

How should Carprieve be stored and disposed of?

How to Store and Dispose of Carprieve

The storage and disposal of Carprieve (carprofen) are strictly defined by regulatory guidelines to ensure stability and safety.

Storage Requirements

Carprieve tablets and caplets must be stored at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F). All forms require protection from light and must be kept in a dry place. Unopened injectable solution requires refrigeration (2 C to 8 C) and must not be frozen. Once the injectable vial is punctured, the contents must be used within 56 days.

Safety and Disposal

The medication must be stored out of the sight and reach of children, and must be secured out of the reach of dogs due to the oral product's palatability. Any unused or expired Carprieve and associated waste must be disposed of in accordance with local and national requirements to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.